Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. Luke JJ, et al. Among authors: tomaszewska kiecana m. Nat Med. 2023 Nov;29(11):2814-2824. doi: 10.1038/s41591-023-02593-0. Epub 2023 Oct 19. Nat Med. 2023. PMID: 37857711 Free PMC article. Clinical Trial.
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N, Cosman R, Banerji U, Rasco D, Tomaszewska-Kiecana M, Garralda E, Kornacki D, Li J, Tian C, Bourayou N, Powderly J. Lakhani N, et al. Among authors: tomaszewska kiecana m. ESMO Open. 2024 Apr;9(4):102254. doi: 10.1016/j.esmoop.2024.102254. Epub 2024 Feb 21. ESMO Open. 2024. PMID: 38387109 Free PMC article. Clinical Trial.
A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Liao M, Jeziorski KG, Tomaszewska-Kiecana M, Láng I, Jasiówka M, Skarbová V, Centkowski P, Ramlau R, Górnaś M, Lee J, Edwards S, Habeck J, Nash E, Grechko N, Xiao JJ. Liao M, et al. Cancer Chemother Pharmacol. 2021 Nov;88(5):887-897. doi: 10.1007/s00280-021-04338-7. Epub 2021 Aug 9. Cancer Chemother Pharmacol. 2021. PMID: 34370076 Free PMC article. Clinical Trial.
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Grechko N, Skarbova V, Tomaszewska-Kiecana M, Ramlau R, Centkowski P, Drew Y, Dziadziuszko R, Zemanova M, Beltman J, Nash E, Habeck J, Liao M, Xiao J. Grechko N, et al. Cancer Chemother Pharmacol. 2021 Aug;88(2):259-270. doi: 10.1007/s00280-021-04278-2. Epub 2021 Apr 28. Cancer Chemother Pharmacol. 2021. PMID: 33909097 Free PMC article. Clinical Trial.
Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults.
Tomaszewska-Kiecana M, Ullmann M, Petit-Frere C, Monnet J, Dagres C, Illes A. Tomaszewska-Kiecana M, et al. Expert Rev Clin Immunol. 2023 Apr;19(4):439-446. doi: 10.1080/1744666X.2023.2174104. Epub 2023 Feb 13. Expert Rev Clin Immunol. 2023. PMID: 36715299 Clinical Trial.
23 results